Medpace Holdings, Inc. $MEDP Position Lowered by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. reduced its position in Medpace Holdings by 1.3% in the first quarter, owning 198,424 shares valued at approximately $60.46 million after selling 2,622 shares.
• Insider trades included Medpace's President and CFO selling significant amounts of stock, with the President selling 41,801 shares and the CFO selling 12,000 shares in transactions that reduced their holdings by 53.38% and 66.67%, respectively.
• Analysts have issued varied ratings for Medpace, with target prices ranging from $328.00 to $510.00, resulting in a consensus rating of "Hold" and an average target price of $406.60.

Charles Schwab Investment Management Inc. lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 198,424 shares of the company's stock after selling 2,622 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Medpace worth $60,458,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares in the last quarter. Assetmark Inc. raised its holdings in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares during the last quarter. Proficio Capital Partners LLC raised its holdings in Medpace by 6.4% in the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock valued at $237,000 after acquiring an additional 47 shares during the last quarter. Park Avenue Securities LLC raised its holdings in Medpace by 1.8% in the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after acquiring an additional 48 shares during the last quarter. Finally, Schulhoff & Co. Inc. raised its holdings in Medpace by 1.9% in the 1st quarter. Schulhoff & Co. Inc. now owns 2,680 shares of the company's stock valued at $817,000 after acquiring an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ MEDP traded up $1.91 during trading hours on Tuesday, hitting $464.82. The company had a trading volume of 136,893 shares, compared to its average volume of 454,068. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of 34.56, a P/E/G ratio of 2.88 and a beta of 1.42. The firm's 50 day moving average is $366.17 and its 200 day moving average is $331.80.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 41,801 shares of the company's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the completion of the transaction, the president directly owned 36,503 shares of the company's stock, valued at $16,539,874.33. This represents a 53.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,788 shares of company stock worth $51,018,354 over the last quarter. Company insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MEDP. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and boosted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. TD Cowen restated a "sell" rating and set a $366.00 price objective (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Truist Financial upped their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price objective on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Finally, Barclays upped their price objective on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average price target of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.